738 Shares in argenex SE $ARGX Acquired by Diversified Trust Co.

Diversified Trust Co. acquired a new position in shares of argenex SE (NASDAQ:ARGX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 738 shares of the company’s stock, valued at approximately $621,000.

Several other large investors also recently added to or reduced their stakes in ARGX. American Century Companies Inc. boosted its position in shares of argenex by 11.6% during the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after acquiring an additional 23,864 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of argenex by 91.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after purchasing an additional 4,217 shares during the period. Allianz Asset Management GmbH grew its holdings in shares of argenex by 21.3% in the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after purchasing an additional 645 shares during the period. Allspring Global Investments Holdings LLC increased its position in argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after purchasing an additional 26,343 shares during the last quarter. Finally, US Bancorp DE increased its position in argenex by 37.2% during the third quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after purchasing an additional 1,919 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Price Performance

Shares of ARGX opened at $691.40 on Friday. The firm has a 50-day simple moving average of $781.05 and a two-hundred day simple moving average of $813.59. The stock has a market cap of $42.78 billion, a PE ratio of 35.42, a P/E/G ratio of 1.14 and a beta of 0.38. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Saturday, February 14th. The company reported $8.02 EPS for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. As a group, sell-side analysts expect that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on ARGX shares. DZ Bank upgraded shares of argenex to a “strong-buy” rating in a report on Friday, December 19th. Morgan Stanley raised their price target on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Citizens Jmp upped their price objective on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Wedbush reiterated an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research report on Monday, March 9th. Finally, Citigroup cut their target price on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $999.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.